SLU-PP-332 is studied as an ERR pathway research compound with interest in exercise-mimetic signaling, mitochondrial metabolism, skeletal muscle pathway models, oxidative energy systems, and metabolic flexibility
Journal of Japanese Society of Anti-Aging Medicine
Citterio CE, Rivolta CM, Targovnik HM
CagriSema leverages synergistic mechanisms: Semaglutide slows gastric emptying, suppresses glucagon, stimulates insulin, and reduces appetite, while Cagrilintide enhances satiety and further delays gastric emptying via brainstem pathways
Sasaninia K, Kelley M, Abnousian A, Badaoui A, Alexander L, Sheren N, Owens J, Rajurkar S, Razo-Botello B, Chorbajian A, Yoon S, Dhama S, Avitia E, Ochoa C, Yutani R, Venketaraman V
This is one of the few direct comparisons in this encyclopedia where the clinical evidence produces a clear recommendation rather than a balanced assessment of trade-offs